Personalized Alzheimer's Disease Prevention and Treatment System
Legal Citation
Summary of the Inventive Concept
A next-generation system for predicting, preventing, and treating Alzheimer's disease, leveraging machine learning, wearable devices, virtual reality, and blockchain technology to provide personalized treatment plans and slow disease progression.
Background and Problem Solved
The original patent disclosed methods for treating mild cognitive impairment and Alzheimer's disease using aluminum salts. However, these methods have limitations, including the need for frequent MMSE assessments and the lack of personalized treatment approaches. The new inventive concept addresses these limitations by introducing a comprehensive system that integrates advanced technologies to provide early detection, prevention, and personalized treatment of Alzheimer's disease.
Detailed Description of the Inventive Concept
The system comprises a machine learning algorithm trained on a dataset of AD patient profiles and biomarkers, which predicts AD progression risk based on patient-specific data and recommends personalized treatment plans. A wearable device monitors AD biomarkers in real-time, transmitting data to a cloud-based analytics platform for analysis and alert generation. A virtual reality-based cognitive training platform provides immersive, gamified exercises to improve cognitive function and slow AD progression. A decentralized, blockchain-based AD patient registry enables secure, decentralized data sharing and collaboration among researchers and clinicians. The system integrates these components to provide a holistic approach to AD prevention and treatment.
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in Alzheimer's disease prevention and treatment by leveraging advanced technologies to provide personalized, data-driven approaches. The machine learning algorithm, wearable device, virtual reality platform, and blockchain-based registry are novel and non-obvious components that differentiate the new inventive concept from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the system could include the use of other AI algorithms, different wearable device designs, or variations of the virtual reality platform. Additionally, the system could be adapted for use in other diseases or conditions, such as Parkinson's disease or traumatic brain injury.
Potential Commercial Applications and Market
The personalized Alzheimer's disease prevention and treatment system has significant commercial potential in the healthcare and pharmaceutical industries. The system could be marketed as a comprehensive solution for AD prevention and treatment, with potential applications in clinical settings, research institutions, and patient care.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurodegenerative disease treatment, medical informatics, and digital health technologies with a focus on Alzheimer's disease diagnostic and therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A multidisciplinary professional with expertise in neuroscience, machine learning, medical device design, and digital health technologies, holding advanced degrees in biomedical engineering, computer science, or related fields, with knowledge of AD biomarkers, diagnostic techniques, and emerging treatment strategies
Obviousness Rationale
A PHOSITA would recognize that the source patent's focus on Alzheimer's disease treatment provides a natural foundation for integrating advanced digital technologies to enhance diagnostic and therapeutic approaches. The PTD's machine learning, wearable monitoring, and personalized treatment strategies represent predictable technological extensions of existing AD research methodologies. The combination of known medical diagnostic techniques with emerging digital technologies would be an obvious progression for improving AD patient care and management.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,568 |
|---|---|
| Title | Treatment and prevention of Alzheimer's disease (AD) |
| Assignee(s) | Advantage Therapeutics, Inc. |